Clinical Trial

Gut Microbiome in DLBCL Treated With Glofitamab

Name: Gut Microbiome in DLBCL Treated With Glofitamab — clinical trial record (NCT07498920)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.

Trial Details

NCT Number	NCT07498920
Lead Sponsor	Peking Union Medical College Hospital
Conditions	DLBCL, Glofitamab, Gut Biome
Enrollment	30 participants
Start Date	2026-04-01
Primary Completion	2029-04-01 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-27